Abstract:Glaucoma is a group of optic neuropathies characterized by the progressive degeneration of retinal ganglion cells (RGCs) as well as their axons leading to irreversible loss of sight. Medical management of the intraocular pressure (IOP) still represents the gold standard in glaucoma therapy, which only manages a single risk factor and does not directly address the neurodegenerative component of this eye disease. Recently, our group showed that antibody-derived immunopeptides (encoding complementarity-determining regions, CDRs) provide attractive glaucoma medication candidates and directly interfere its pathogenic mechanisms by different modes of action. In accordance with these findings, the present study showed the synthetic complementary-determining region 2 (CDR2) peptide (INSDGSSTSYADSVK) significantly increased RGC viability in vitro in a concentration-dependent manner (p < 0.05 using a CDR2 concentration of 50 μg/mL). Employing state-of the-art immunoprecipitation experiments, we confirmed that synthetic CDR2 exhibited a high affinity toward the retinal target protein histone H3.1 (HIST1H3A) (p < 0.001 and log2-fold change > 3). Furthermore, molecular dynamics (MD) simulations along with virtual docking analyses predicted potential CDR2-specific binding regions of HIST1H3A, which might represent essential post-translational modification (PTM) sites for epigenetic regulations. Quantitative mass spectrometry (MS) analysis of retinas demonstrated 39 proteins significantly affected by CDR2 treatment (p < 0.05). An up-regulation of proteins involved in the energy production (e.g., ATP5F1B and MT-CO2) as well as the regulatory ubiquitin proteasome system (e.g., PSMC5) was induced by the synthetic CDR2 peptide. On the other hand, CDR2 reduced metabolic key enzymes (e.g., DDAH1 and MAOB) as well as ER stress-related proteins (e.g., SEC22B and VCP) and these data were partially confirmed by microarray technology. Our outcome measurements indicate that specific protein-peptide interactions influence the regulatory epigenetic function of HIST1H3A promoting the neuroprotective mechanism on RGCs in vitro. In addition to IOP management, such synthetic peptides as CDR2 might serve as a synergistic immunotherapy for glaucoma in the future.

Neuroprotection of a Novel Cyclopeptide CHSDGIC from the Cyclization of PACAP (1-5) in Cellular and Rodent Models of Retinal Ganglion Cell Apoptosis.

Effects of Cyclopeptide CHSDGIC from the Cyclization of PACAP (1–5) on the Proliferation and UVB-induced Apoptosis of the Retinal Ganglion Cell Line RGC-5

CHSDGIC from Cyclization of PACAP (1-5) Attenuates UVB-induced Apoptosis of Human Retinal Pigment Epithelial Cells

PACAP Attenuates Optic Nerve Crush-Induced Retinal Ganglion Cell Apoptosis Via Activation of the CREB-Bcl-2 Pathway

Protective Effects of Protocatechuic Acid on Retinal Ganglion Cells from Oxidative Damage Induced by H2O2

Protective Effects of Pituitary Adenylate-Cyclase-Activating Polypeptide on Retinal Vasculature and Molecular Responses in a Rat Model of Moderate Glaucoma

Protective Effect of Mitochondria-Targeted Peptide MTP-131 Against Oxidative Stress-Induced Apoptosis in RGC-5 Cells

Injectable Gel-PEG hydrogels as promising delivery system for intravitreal PACAP release: Novel therapeutics for unilateral common carotid artery occlusion induced retinal ischemia

PACAP-derived Mutant Peptide MPAPO Protects Trigeminal Ganglion Cell and the Retina from Hypoxic Injury Through Anti-Oxidative Stress, Anti-Apoptosis, and Promoting Axon Regeneration.

Neuroprotective Effects of Cic-3 Chloride Channel in Glutamate-Induced Retinal Ganglion Cell Rgc-5 Apoptosis

N-Acetylcysteine Protects Against Hypoxia Mimetic-Induced Autophagy by Targeting the HIF-1α Pathway in Retinal Ganglion Cells

Targeted Microglial Attenuation through Dendrimer-Drug Conjugates Improves Glaucoma Neuroprotection

Pituitary Adenylate Cyclase Activating Polypeptide Elicits Neuroprotection Against Acute Ischemic Neuronal Cell Death Associated with NMDA Receptors

Platelet-derived Growth Factor (PDGF)-C Inhibits Neuroretinal Apoptosis in a Murine Model of Focal Retinal Degeneration

Elevation of P-Nr2as1232 by Cdk5/p35 Contributes to Retinal Ganglion Cell Apoptosis in a Rat Experimental Glaucoma Model

Reversal of injury-associated retinal ganglion cell gene expression by a phosphodiesterase anchoring disruptor peptide

Synthetic antibody-derived immunopeptide provides neuroprotection in glaucoma through molecular interaction with retinal protein histone H3.1

Effects of Pituitary Adenylate Cyclase Activating Polypeptide and Its Fragments on Retinal Degeneration Induced by Neonatal Monosodium Glutamate Treatment

[Protection of Autoimmunity Induced by Copolymer-1 on Optic Nerve: Experiment with Rat Glaucoma Models].

A Novel Cyclopeptide from the Cyclization of PACAP(1–5) with Potent Activity Towards PAC1 Attenuates STZ-induced Diabetes

Interactive Effects of C3, Cyclic AMP and Ciliary Neurotrophic Factor on Adult Retinal Ganglion Cell Survival and Axonal Regeneration

Neuroprotection of a Novel Cyclopeptide C*HSDGIC* from the Cyclization of PACAP (1-5) in Cellular and Rodent Models of Retinal Ganglion Cell Apoptosis.

Effects of Cyclopeptide C*HSDGIC* from the Cyclization of PACAP (1–5) on the Proliferation and UVB-induced Apoptosis of the Retinal Ganglion Cell Line RGC-5

C*HSDGIC* from Cyclization of PACAP (1-5) Attenuates UVB-induced Apoptosis of Human Retinal Pigment Epithelial Cells